TriNetX and Fujitsu Collaborate to Enhance Access to Life-Saving Medications for Japanese Patients
TriNetX and Fujitsu Forge a New Path in Healthcare Innovation in Japan
On February 12, 2025, an important collaboration was announced between TriNetX, a leading global provider of real-world data (RWD) solutions, and Fujitsu, one of Japan's major electronic medical records providers. Together, they have established a new entity named TriNetX Japan K.K., aiming to enhance patient access to life-altering medications using advanced data analytics and real-world evidence.
This groundbreaking joint venture is designed to accelerate the drug development process by utilizing anonymized electronic medical records from Japanese patients. By leveraging these data, the collaboration seeks to optimize clinical trials and advance health research within the country. The initiatives taken in this partnership highlight Japan's growing role in the international landscape of data-driven healthcare and its commitment to pharmaceutical innovation.
Japan stands as the third-largest pharmaceutical market globally and is uniquely positioned due to its rapidly aging population, providing a valuable opportunity to study age-related diseases such as cancer and cardiovascular disorders. Gadi Lachman, the CEO of TriNetX, emphasized the significance of this partnership by stating that since entering the Japanese market in 2022, the firm has successfully enabled pharmaceutical companies and researchers to securely access anonymized patient data, thus complying with the stringent data privacy laws in Japan.
The TriNetX Japan K.K. initiative integrates the TriNetX LIVE™ platform, a global network with over 200 million patient records, alongside Fujitsu’s cloud computing resources dedicated to the healthcare sector in Japan. This integration creates a seamless connection between major medical institutions and life sciences innovators. Enhanced access to vast datasets will revolutionize clinical research by streamlining trials and initiatives focused on precision medicine.
Tatsuki Araki, Fujitsu’s head of the
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.